[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsons-disease-pd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsons-disease-pd":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,72,0,25,[9,46,71,99,134,155,183,207,240,268,295,316,342,375,401,424,447,481,505,525,547,573,596,615,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100652408","stn-ttis-with-different-intervention-intervals-versus-standard-medical-treatment-for-parkinsons-disease-100652408",false,"NCT07774312","STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease","STN-targeted Temporal Interference Stimulation With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease: A Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n* 1.Aged 50-85 years, male or female.\n* 2.Diagnosed with idiopathic Parkinson disease (PD) in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Parkinson's Disease (4th Edition), with a confirmed diagnosis for at least 6 months and a stable condition, defined as no significant deterioration or major medication adjustment within the past month.\n* 3.Receiving stable doses of antiparkinsonian medication (e.g., levodopa or dopamine agonists) and willing to maintain the medication regimen during the study.\n* 4.Hoehn and Yahr stage 1-3 in the medication ON state.\n* 5.Baseline MDS-UPDRS Part III total score ≥20 in the medication ON state.\n* 6.No history of non-invasive neuromodulation therapy, or discontinuation of such therapy for at least 3 months before enrollment if previously received.\n* 7.Normal cognitive function (MoCA score ≥24) and able to cooperate with tTIS intervention, clinical scale assessments, and basic smartphone- and smartwatch-assisted home-based motor self-assessments.\n* 8.Able and willing to provide written informed consent and complete all required study procedures and follow-up assessments.\n\nExclusion Criteria:\n\n* 1.Other neurological disorders that may affect motor or cognitive function.\n* 2.Contraindications to magnetic resonance imaging (MRI), such as claustrophobia.\n* 3.History of taking antipsychotics, antidepressants, or other medications affecting dopamine levels.\n* 4.Psychiatric disorders (e.g., depression or schizophrenia), substance abuse, or alcohol dependence.\n* 5.Implanted medical devices (e.g., pacemaker or defibrillator), metal implants in the cranium or spine, a personal or family history of epilepsy, or severe skull defects.\n* 6.Previous deep brain stimulation (DBS) or other intracranial implantation surgery, or participation in another Parkinson disease clinical trial within the past 3 months.","ALL","50 Years","85 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to compare the efficacy and safety of different Intervention Intervals of subthalamic nucleus-targeted transcranial temporal interference stimulation (STN-tTIS) in patients with Parkinson disease.\n\nPrevious studies suggest that STN-tTIS may improve motor symptoms in people with Parkinson disease. However, most previous studies evaluated only one stimulation session. It remains unclear how often STN-tTIS should be administered during a repeated treatment course and whether shorter intervention intervals stimulation produces greater or longer-lasting improvement without increasing adverse events.\n\nThe main questions this study aims to answer are:\n\n1. Does STN-tTIS administered five times weekly improve motor symptoms more than standard medication treatment alone at the end of the 2-week treatment period?\n2. Do once-weekly, twice-weekly, and five-times-weekly STN-tTIS produce different changes in motor symptoms?\n3. Does the STN-tTIS intervention intervals influence how long its effects persist after treatment?\n4. Do the different intervention intervals have different effects on non-motor symptoms, quality of life, cognitive function, and safety?\n\nParticipants will be randomly assigned to receive STN-tTIS once weekly, twice weekly, or five times weekly for 2 weeks, or to continue standard antiparkinsonian medication without additional stimulation. All participants will maintain a stable medication regimen during the study. Their motor and non-motor symptoms will be assessed during the treatment period and during a subsequent 2-week follow-up period.",[28],"Parkinson's Disease (PD)",[30,31,32],"Subthalamic nucleus","Transcranial Temporal Interference Stimulation","Intervention Intervals","RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2026-07-27",{"date":41,"type":22},"2027-04-15",{"name":43,"class":44},"Ruijin Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100647273","a-novel-digital-music-based-autonomous-personalized-walking-intervention-to-improve-gait-and-walking-automaticity-in-parkinson-disease-100647273","NCT07705373","A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease","MyMusiQ","Inclusion Criteria:\n\n* Self-report of diagnosis of typical Parkinson disease determined by a medical doctor\n* ≥ 40 years of age\n* Community-dwelling (e.g. home, independent living, senior housing)\n* Have stable PD medications for at least two weeks prior to enrollment\n* Modified Hoehn and Yahr stages 1-3 per physical exam by a licensed physical therapist\n* Able to walk independently without physical assistance for at least 10 minutes (assistive devices allowed with reciprocal gait pattern)\n* Willing and able to provide informed consent\n* Provide HIPAA Authorization to allow communication with the primary healthcare provider for communication (as needed) during the study period\n\nExclusion Criteria:\n\n* \\\u003C 40 years of age\n* Diagnosis of atypical Parkinsonism\n* Modified Hoehn and Yahr stages 4-5\n* Significantly disturbing freezing episodes during daily walking based on the New Freezing of Gait Questionnaire (Part III Item 7)\n* Fall frequencies \\>1x\u002Fweek on average, over the past month.\n* Currently participating in physical therapy for Parkinson gait rehabilitation\n* Currently performing walking exercise at moderate intensities or higher for at least 30 min. per session ≥ 3x\u002Fweek\n* Self-reported cardiac problems that interfere with the ability to safely exercise (e.g., congestive heart failure, uncontrolled cardiac arrhythmias, chest pain;\n* Orthopedic problems in the lower extremities or spine that may limit walking distance (e.g., severe arthritis, spinal stenosis, or significant pain)\n* Any other medical conditions that would preclude successful participation as determined by the researcher\u002F physical therapist\n* Cognitive impairment (i.e., Montreal Cognitive Assessment, MoCA \\\u003C 21)\n* Unable to walk independently (i.e., without physical assistance) at a comfortable speed ≥ 0.4m\u002Fs as measured using the 10-meter Walk Test (10mWT) as examined in Baseline #1\n* Resting tachycardia (\\> 100 beats\u002Fmin) or uncontrolled blood pressure (resting systolic BP \\> 160 mmHg or diastolic BP \\>100 mmHg)) as measured by the researcher\u002F physical therapist\n* Unable to independently use the music-based digital therapeutic during training\n* Significant hearing impairment","40 Years",{"count":55,"type":22},200,[25],"The purpose of this research study is to examine the effects of a 3-month personalized community-based walking program called MyMusiQ. The study uses music cues delivered through a digital device in people with Parkinson disease (PD). The investigators want to know if personalized music cueing through the digital device can improve walking quality, walking ability, daily walking amount and intensity, and quality of life, while helping walking feel more automatic and require less mental effort. Participants will take part in this research study for approximately 18 weeks in total. During this time, participants will complete 4 study visits at designated research centers at Boston University, Washington University in St. Louis, or the University of Utah, depending on the site of enrollment.",[28],[60,61,62,63,28],"Music-based intervention","Gait quality","Walking capacity","Gait automaticity",{"date":36,"type":37},{"date":34,"type":37},{"date":67,"type":22},"2029-02-28",{"name":69,"class":44},"Boston University Charles River Campus",3,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100652567","impact-of-subthalamic-nucleus-deep-brain-stimulation-on-cognitive-and-psychiatric-symptoms-in-parkinsons-disease-100652567","NCT07777419","Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease","PD-COGPSY-DBS","Inclusion Criteria:\n\n* Diagnosed with Parkinson's disease\n* Treated with subthalamic nucleus deep brain stimulation (STN-DBS)\n* For part I: General research consent for the analysis of routine clinical data\n* For part II of the study: ability to provide informed consent\n* native German or French speaker\n* Montreal Cognitive Assessment with score ≥ 20\n\nExclusion Criteria:\n\n* Atypical Parkinsonism\n* Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.)\n* Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment\n* Schizophrenia, ongoing substance abuse, bipolar disorder or autism\n* For part II: Severe depressive disorder and\u002For suicidality\n* Insufficient quality or lack of brain imaging data pre and\u002For post STN-DBS","18 Years","75 Years",{"count":81,"type":22},20,[25],"With this study, the investigators want to investigate how deep brain stimulation (DBS) affects various cognitive and psychiatric symptoms of Parkinson's disease (PD). In particular, they will examine whether stimulation of the left hemisphere has a different effect than stimulation of the right hemisphere on cognitive and psychiatric symptoms.",[85],"Parkinsons Disease (PD)",[87,88,89],"Deep Brain Stimulation","Neuropsychiatric symptoms","Cognition","NOT_YET_RECRUITING","2026-08-18",{"date":34,"type":37},{"date":94,"type":22},"2026-08-01",{"date":96,"type":22},"2028-12-31",{"name":98,"class":44},"Insel Gruppe AG, University Hospital Bern",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":133},"100638891","phase-1-a-phase-i-study-in-healthy-volunteers-and-parkinsons-disease-pd-patients-100638891","NCT07630545","A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.","A Multi-part, Adaptive Phase 1, First Time in Human Study in Healthy Volunteers to Assess Safety, Tolerability and Pharmacokinetics (PK) Following Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) of MTX325, Including Option to Assess: a Single Dose in Elderly Participants; Multiple Doses in Patients With Parkinson's Disease (PD); Central Nervous System (CNS) Penetration, Biodistribution, and Biomarkers; and the Effect of Food on PK.","PART 5 - Currently recruiting in Parkinson's Disease Patients\n\nInclusion Criteria\n\n1. Male and female participants aged ≥ 40 to ≤ 75 years.\n2. Male or female participants. Female participants of childbearing potential must be willing to use highly effective forms of contraception (refer to Section 9.7.1 for details on highly effective methods of contraception and definitions of women of childbearing potential and of fertile men):\n3. Body mass index (BMI) between 18 and 34.0 kg\u002Fm2, inclusive.\n4. If being treated with selective serotonin reuptake inhibitors (SSRIs) for anxiety\u002F depression, must be on a stable dose for 60 days prior to Day -1 and must remain on that dose for the remainder of the study.\n5. Must have had other causes of Parkinsonism excluded\n6. No clinically significant history of previous allergy\u002F sensitivity to MTX325 or any of the excipients contained within the IMP.\n7. Participant with a negative urinary drugs of abuse (DOA) screen (excluding alcohol).\n8. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen \\[HbsAg\\]) and hepatitis C virus antibody (HCV Ab) test results at Screening.\n9. No history of torsade de pointes or long QT syndrome and no heart failure, hypokalaemia, or any other additional cardiac risk factors if judged clinically significant in the opinion of the Investigator.\n10. No clinically significant abnormalities in vital signs during the screening period.\n11. Able to perform all protocol assessments and comply with the study visit schedule.\n12. Able and willing to provide informed consent.\n13. Clinically established PD as per MDS Criteria\\[\n14. Absence of dementia as shown by a baseline Montreal Cognitive Assessment (MoCA®)\n\nExclusion Criteria\n\n1. A clinically significant history of gastrointestinal disorders or any significant medical conditions that would be likely to influence IMP absorption, or evidence of clinically significant central nervous system, respiratory, cardiovascular or metabolic dysfunction or other significant medical conditions with potential to impact participant safety or hinder interpretation of study results.\n2. Clinically significant neurologic disorder other than PD, including history of stroke within 12 months of Screening, seizure within 5 years of Screening, or head trauma with loss of consciousness within 6 months of Screening.\n3. Those with known PD risk genes (per medical history).\n4. Reside in a nursing home or assisted care facility.\n5. No more than 2 PD related freezing episodes or falls in the past 6 months.\n6. Any condition that may predispose participant to complications or technical difficulty with lumbar puncture, in the opinion of the Investigator.\n7. Participants who have conditions that would preclude a lumbar puncture (LP), such as a local infection at the site\n8. Participant who has a history of clinically significant hypersensitivity to local anaesthesia, or its derivatives used during CSF collection or to any medication used to prepare the area of LP.\n9. Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale \\[C-SSRS©\\]\n10. Participants should not be in receipt of any known MATE2k substrates\n11. Plan to receive or administration of rotigotine, catechol-o-methyltransferase (COMT) inhibitors (e.g., entacapone, tolcapone or opicapone), neuroleptics, venlafaxine, NMN, nicotinamide riboside or non-selective Monoamine oxidase \\[MAO\\] inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose and during the study conduct.\n12. Clinically significant abnormal test results for serum biochemistry, haematology, coagulation and\u002For urine analyses as determined within 45 days before first dose of IMP.\n13. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.\n14. Participant has any condition that, in the opinion of the investigator, is clinically significant and may put the participant at greater safety risk, influence response to study product, or interfere with study assessment.\n15. Inability to communicate well with the Investigators.\n16. Participation (dosed) in a NCE clinical study within the previous 3 months or five half lives\n17. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.\n18. Female participants who are pregnant, breastfeeding or lactating.\n19. Clinically significant abnormalities in 12-lead electrocardiogram (ECG)\n20. Participants with recent COVID-19 infection without resolution of symptoms\n21. Participants who have received a COVID-19 vaccine injection from the Screening visit up to first dose of IMP\n22. A clinically significant history of drug or alcohol abuse within the past 2 years.\n23. Currently prescribed treatment for Parkinson's Disease symptoms.\n24. Any history of allergy\u002Fatopy including drug-induced allergy history of severe cutaneous adverse reaction or other type 4\u002Fdelayed-type hypersensitivity.\n25. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.\n26. Previous history of Erythema Multiforme and\u002For identified current risk factor(s) for Erythema Multiforme\n27. Participant has any contra-indication to PET or MRI as determined by screening procedures and PET and MRI safety questionnaires as conducted by the site.\n28. Clinically significant history of previous allergy\u002F sensitivity to \\[18F\\] FDG.\n29. Participants who have had previous exposure to ionizing radiation\n30. Chronic kidney disease defined as glomerular filtration rate (GFR) 1.5 × the upper limit of normal (ULN) or ALT or AST \\>3 × ULN or if participant has Child-Pugh Class C cirrhosis or equivalent severe hepatic impairment.\n31. Hepatic disease or altered liver function as defined by total bilirubin \\>1.5 × the upper limit of normal (ULN) or ALT or AST \\>3 × ULN or if participant has Child-Pugh Class C cirrhosis or equivalent severe hepatic impairment.\n32. Patients with uncontrolled type I or type II diabetes (insulin or non-insulin dependent).\n33. Current symptomatic Hay fever or any history of hay fever involving more than nose and eyes.\n\nPART 1, 2 ,4 - COMPLETED\n\nInclusion Criteria:\n\n1. Healthy male and female (Part 1-2 only) participant, aged ≥ 18 to ≤ 55 years.\n2. Female participant of childbearing potential (Part 1-2 only)\n3. Female participant of non-childbearing potential (Part 1-2 only).\n4. Female participant (Part 1-2 only) with a negative pregnancy test at Screening visit.\n5. Female participant of menopausal status (Part 1-2 only) confirmed by demonstrating at Screening that the serum level of the follicle stimulating hormone (FSH) falls within the respective pathology reference range.\n6. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception\n7. Participant with a body weight of at least 50.0 kg and body mass index (BMI) of 1832 kg\u002Fm2. BMI = body weight (kg) \u002F \\[height (m)\\]2.\n8. No clinically significant history of previous allergy \u002F sensitivity to MTX325 or any of the excipients contained within the IMP.\n9. No clinically significant abnormal test results for serum biochemistry, haematology, coagulation\n10. Participant with a negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 35 days (45 days Part 4 only) before first dose of IMP.\n11. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen \\[HbsAg\\]) and hepatitis C virus antibody (HCV Ab) test results at Screening.\n12. No clinically significant abnormalities in 12-lead electrocardiogram (ECG)\n13. No clinically significant abnormalities in vital signs\n14. Participant must be available to complete the study (including all follow-up visits).\n15. Participant must satisfy an Investigator about his\u002Fher fitness to participate in the study.\n16. Participant must provide written informed consent to participate in the study.\n17. Participants with a negative COVID-19 test on admission (if required).\n18. Part 4 only: Participant with normal MRI performed within 3 months of dosing, as judged by the investigator.\n\nPart 4 - COMPLETED\n\n1. Participants who have had previous exposure to ionizing radiation from research studies\n2. Participant has any contraindication to arterial line insertion\n3. Inability to lie supine for up to 120 mins for PET procedures.\n4. Participant has any contra-indication to MRI as determined by screening procedures and MRI safety questionnaire\n5. Participant suffers from claustrophobia or needle phobia.\n6. Any history of allergy\u002Fatopy including drug-induced allergy or any history of severe cutaneous adverse reaction or other type 4\u002Fdelayed-type hypersensitivity.\n7. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.\n8. Previous history of Erythema Multiforme and\u002For identified current risk factor(s) for Erythema\n\nPart 3 - COMPLETED\n\n1. Healthy male and female participant, ≥ 65 years of age.\n2. Female participant of non-childbearing potential.\n3. Female participant of menopausal status confirmed by demonstrating at Screening that the serum level of the follicle stimulating hormone (FSH) falls within the respective pathology reference range.\n4. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception\n5. Participant with a body weight of at least 50.0 kg and BMI of 18-32 kg\u002Fm2.\n6. No clinically significant history of previous allergy \u002F sensitivity to MTX325 or any of the excipients contained within the IMP.\n7. No clinically significant abnormal test results for serum biochemistry, haematology and\u002For urine analyses determined within 35 days before first dose of IMP.\n8. Participant with an estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation \\>60 mL\u002Fmin\u002F1.73 m2.\n9. Participant with a negative urinary drugs of abuse (DOA)\n10. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen \\[HbsAg\\]) and hepatitis C virus antibody (HCV Ab) test results at Screening.\n11. No clinically significant abnormalities in 12-lead electrocardiogram (ECG)\n12. No clinically significant abnormalities in vital signs\n13. Participant must be available to complete the study (including all follow-up visits).\n14. Participant must satisfy an Investigator about his\u002Fher fitness to participate in the study.\n15. Participant must provide written informed consent to participate in the study.\n\nExclusion Criteria (Part 1, 2, 4) - COMPLETED\n\n1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.\n2. Use of prescription or non-prescription drugs, excluding allowable drugs and contraception\n3. Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale \\[C-SSRS©\\] him\u002Fherself or others - Part 2 only.\n4. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.\n5. A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units\n6. Inability to communicate well with the Investigators\n7. Participation (dosed) in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives\n8. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.\n9. Vegans, vegetarians or other dietary restrictions (Part 1 food effect evaluation, only).\n10. Users of nicotine products\n11. Participants with an excessive habitual daily intake of caffeine\n12. Female participants who are pregnant, breastfeeding or lactating (Part 1-2 only).\n13. Participants with veins unsuitable for venepuncture and cannulation.\n14. Participants with recent COVID-19 infection without resolution of symptoms\n15. Participants who have received a COVID-19 vaccine injection\n\nPart 1 Treatment Period 2a (CSF sampling) Cohort(s) only:\n\n1. Participants who have criteria that would preclude a lumbar puncture (LP)\n2. Participant who has a history of clinically significant hypersensitivity to local anaesthesia\n3. Participant who has a history of clinically significant or major back pathology (lumbar) surgery\n\nPart 4 - COMPLETED\n\n1. Participants who have had previous exposure to ionizing radiation from research studies, such that, in combination with the exposure from this study, their exposure will be \\>10 mSv for the previous 12 months.\n2. Participant has any contraindication to arterial line insertion\n3. Inability to lie supine for up to 120 mins for PET procedures.\n4. Participant has any contra-indication to MRI\n5. Participant suffers from claustrophobia or needle phobia.\n6. Any history of allergy\u002Fatopy\n7. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.\n8. Previous history of Erythema Multiforme and\u002For identified current risk factor(s) for Erythema Multiforme\n\nPart 3 - COMPLETED\n\n1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.\n2. Evidence of febrile illness within 1 week of first dose of IMP.\n3. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements or any medication known to prolong the QT\u002FQTc interval within 35 days or 5 half-lives\n4. Evidence of clinically significant renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.\n5. History of torsade de pointes, heart failure, hypokalaemia, long QT syndrome or any other additional cardiac risk factors.\n6. A clinically significant history of drug or alcohol abuse\n7. Participants with an excess habitual daily intake of caffeine\n8. Inability to communicate well with the Investigators\n9. Participation in a NCE clinical study within the previous 3 months or five half-lives\n10. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.\n11. Participants who have received a COVID-19 vaccine injection within 35 days prior to first dose of IMP.\n12. Users of nicotine products\n13. Participants with veins unsuitable for venepuncture and cannulation.\n14. Participants with recent COVID-19 infection with resolution of symptoms",true,{"count":108,"type":22},106,[110],"PHASE1","The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.",[28,113,114],"Mild to Moderate Parkinson's Disease","Early Stage Parkinson's Disease",[116,117,118,119,120,121,122,123],"Parkinson's disease","MDS-UPDRS","CSF","Plasma","Biomarkers","Mild","Moderate","Hoehn and Yahr scale",{"date":125,"type":37},"2026-08-19",{"date":127,"type":37},"2023-11-30",{"date":129,"type":22},"2027-12-27",{"name":131,"class":132},"Mission Therapeutics","NETWORK",18,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":45},"100606466","research-into-the-expression-of-the-csga-gene-and-how-it-changes-in-patients-with-parkinsons-disease-100606466","NCT07175922","Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease","Evaluation of csgA Prevalence, Gene Expression and Week-to-Week Variability in Participants With Parkinson's Disease and a History of Gastrointestinal Dysfunction","Inclusion Criteria:\n\n* Between 18-80 years of age at ICF signing (inclusive)\n* A diagnosis of PD within 10 years from the time of ICF signing\n* Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment\n* All participants must understand and provide written informed consent prior to any study specific procedures\n* Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments\n\nExclusion Criteria:\n\n* Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance\n* Recent GI infection in the past 3 months if deemed clinically significant by the investigator.\n* Major GI surgery (excluding appendectomy\u002Fcholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator\n* Any known current or past eating disorder if deemed clinically significant by the investigator\n* Use of systemic antibiotics within 30 days prior to enrollment","80 Years",{"count":55,"type":22},"OBSERVATIONAL","This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.",[85],"2026-08-17",{"date":125,"type":37},{"date":149,"type":37},"2025-09-25",{"date":151,"type":22},"2026-11-30",{"name":153,"class":154},"Vertero Therapeutics","INDUSTRY",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":45},"100617766","phase-2-a-phase-2-study-to-assess-the-effects-of-sul-238-on-high-energy-phosphates-with-p-mrs-in-patients-with-early-untreated-parkinsons-disease-100617766","NCT07322887","A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease","A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the Effects of SUL-238 on High Energy Phosphates With Magnetic Resonance Spectroscopy (³¹P-MRS) in Patients With Early, Untreated Parkinson's Disease (\"SHEPHERD\" STUDY)","SHEPHERD","Inclusion Criteria:\n\n1. Untreated Parkinson's Disease (PD) patients diagnosed in accordance with the UK PDS Brain Bank Criteria for the diagnosis of PD. Patients must have bradykinesia and at least one of the following:\n\n   1. muscular rigidity\n   2. rest tremor (4-6 Hz)\n   3. postural instability unrelated to primary visual, cerebellar, vestibular or proprioceptive dysfunction.\n2. The duration of PD since diagnosis is ≤ 1 year.\n3. Patients with Modified Hoehn and Yahr stage ≤ 2.0.\n4. Patients with Montreal Cognitive Assessment (MOCA) score of ≥22.\n5. Men and women aged ≥40 years at screening.\n6. Able to understand the nature of the study and provide signed and dated written informed consent in accordance with local regulations before the conduct of any study related procedures.\n7. Able to complete all study related testing and evaluations.\n8. Patients must be, in the opinion of the Investigator, able to participate in all scheduled evaluations, likely to complete all required tests, and likely to be compliant.\n9. Men and women of child-bearing potential with partners of child-bearing potential must agree to use highly effective contraception. For male patients, contraception should continue for 3 months after the last dose of investigational medicinal product (IMP, one spermatic cycle). For female patients, contraception should continue for 6 months after the last dose of IMP (one oocyte cycle).\n10. Women of non-childbearing potential must be post-menopausal (the last menstrual period was at least 12 months ago, and follicle-stimulating hormone \\[FSH\\] at screening confirms post-menopausal status), or have no uterus, ovaries, or fallopian tubes (or have their fallopian tubes tied). All women must have a negative pregnancy test result before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.\n\nExclusion Criteria:\n\n1. Atypical parkinsonism, including that due to drugs, metabolic disorders, encephalitis, cerebrovascular disease, normal pressure hydrocephalus, or other neurodegenerative disease.\n2. Any history of intellectual disability or psychiatric disorders, including substance use disorders, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, except a history of mild depression\u002Fanxiety that has been resolved for at least the past 3 months.\n3. A positive answer to questions 3 through 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening.\n4. A positive Hepatitis B surface antigen, Hepatitis C antibody, or Human Immunodeficiency Virus (HIV) antibody test at screening.\n5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal (ULN) at screening or between screening and first dose administration.\n6. Received or used an investigational product (including placebo) or device within the following time period prior to day -1 in the current study: 90 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).\n7. Use of non-prescription drugs, vitamins, herbal, and dietary supplements which has potential to influence the mitochondrial function (such as coenzyme Q10, carnitine, creatine, lipoic acid and vitamin E) within 30 days prior to day -1.\n8. Use of drugs which are strong inhibitors of CYP3A4 or CYP3A4 substrates with narrow therapeutic index within 30 days prior to day -1.\n9. History of clinically significant sensitivity to any of the study medications, or components thereof or a history of drug or other allergies that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.\n10. Women with a positive pregnancy test, are lactating, or are planning to become pregnant during the study or within 6 months of the end of this study.\n11. A history or presence of any disease, condition, or surgery likely to affect drug absorption, distribution, metabolism, or excretion. Patients with a history of cholecystectomy should be excluded.\n12. A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, pulmonary, ophthalmologic, immunologic, hematologic, dermatologic, or neurologic (other than PD) abnormality.\n13. At screening, any clinically significant abnormalities in rhythm, conduction, or morphology of the resting 12-lead ECG.\n14. A clinically significant vital signs abnormality at screening or day -1, as determined by the investigator in accordance with the Dutch General Practitioner Guidelines (NHG Standards), corresponding to higher than 160 mm Hg systolic and 110 mm Hg diastolic blood pressure. Participants with a systolic blood pressure \\\u003C90 mmHg or a diastolic blood pressure \\\u003C50 mmHg will also be excluded.\n15. In the opinion of the Investigator or Medical Monitor, the patient is unlikely to comply with the protocol or is unsuitable for any reason, e.g., known issues with ability to swallow tablets.\n16. Women of child-bearing potential (WOCBP), or men, who are unwilling or unable to use accepted methods of birth control for up to 6 months following study participation.\n17. Contraindications for undergoing an MRI.",{"count":164,"type":22},45,[166],"PHASE2","The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan. It will also learn about the safety of new drug SUL-238. The main questions it aims to answer are:\n\n* Does new drug SUL-238 improve the mitochondrial function in patients with Parkinson's Disease (PD)?\n* What medical problems do participants have when taking new drug SUL-238?\n\nResearchers will compare new drug SUL-238 to a placebo (a look-alike substance that contains no drug) to see if SUL-238 works to improve mitochondrial function in patients with PD.\n\nParticipants will:\n\n* Take new drug SUL-238 or a placebo every day for 28 days\n* Visit the clinic once every 2 weeks for checkups and tests during the treatment period and finally 28 days after the last dose of SUL-238\n* Keep a diary of their symptoms and the number of times they use oral new drug SUL-238",[28],[170,171,172,173,174],"Phase 2","SUL-238","Mitochondrial function","Magnetic Resonance Spectroscopy","MRS","2026-08-13",{"date":146,"type":37},{"date":178,"type":37},"2026-05-21",{"date":180,"type":22},"2027-07-31",{"name":182,"class":154},"GEN İlaç ve Sağlık Ürünleri A.Ş.",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":141,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100650001","phase-3-phase--clinical-trial-to-evaluate-the-efficacy-and-safety-of-tj0113-capsules-in-patients-with-early-onset-parkinsons-disease-100650001","NCT07741045","Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease","A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease","Inclusion Criteria:\n\n1. Participants who voluntarily participate in the clinical trial, and have signed the ICF, are able to understand and follow the study protocol, willing to visit the study site on time, fully understand the content, process and potential adverse reactions of the study, and indicate the date of signing the ICF;\n2. Male or female aged 18 to 80 years (inclusive) at the time of signing the ICF;\n3. Meets the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria for primary PD\\[1\\] or the 2016 Chinese diagnostic criteria for Parkinson's disease\\[13\\]; with an age of onset ≤50 years, diagnosed as EOPD;\n4. Able to cooperate in completing the \"off\" time records in the diary card;\n5. Modified Hoehn-Yahr stage 1\\~2.5 (inclusive) in the \"off\" state at screening;\n6. Has been stably receiving anti-PD treatment before baseline and agrees to keep the original anti-PD medication unchanged during the trial; at the time of randomization, the investigator judges that the current treatment regimen has achieved optimal disease management status;\n\n   \\- \"Stably receiving anti-PD treatment\" is defined as: 1) Must use levodopa, may be combined with other anti-PD medications; 2) The type and name of anti-PD medications used by the participant have remained unchanged for at least 3 months prior to the baseline visit, and the dose has remained unchanged for at least 1 month prior to the baseline visit; 3) In this trial: No planned dose regimen adjustments during the double-blind treatment period; changes to the dose of stably received anti-PD medications are discouraged during the open-label treatment period, but if necessary, the dose may be adjusted at the discretion of the investigator.\n7. MDS-UPDRS Part III score ≥22 in off-anti-PD medication state at screening;\n8. Participants of childbearing potential (including spouses of male participants) who have no childbearing or sperm donation plan from the end of the screening period to within 6 months after the last dose and are willing to use at least one effective method (see Appendix I for details) for contraception.\n\nExclusion Criteria:\n\n1. Presence of any medical condition that may interfere with full participation in the study, including but not limited to the following: medical history of epilepsy or any complications, medical history of hemolytic anemia, pulmonary embolism, respiratory depression, active psychiatric disease, or malignancy; positive tumor marker detection results at screening and judged by the investigator to be clinically significant;\n2. Participants who have experienced a New York Heart Association (NYHA) Class III or above congestive heart failure, unstable angina pectoris, acute myocardial infarction, hemorrhagic stroke, and ischemic stroke (including transient ischemic attack) within 6 months before screening; or those who have undergone any percutaneous coronary intervention or coronary artery bypass grafting, heart valve repair\u002Freplacement; or those with severe arrhythmia as judged by the investigator at the time of screening;\n3. A personal or family history of long QT syndrome, a family history of sudden death in first-degree relatives (parents, offspring, and siblings) before the age of 40; and\u002For a personal history of unexplained syncope within 1 year prior to screening; and\u002For QTcF \\>450 ms (male) or QTcF \\>470 ms (female) based on resting ECG results at screening;\n4. Participants with unstably controlled hypertension at screening, defined as the systolic blood pressure ≥ 160 mmHg and\u002For the diastolic blood pressure ≥ 100 mmHg (verify before randomization);\n5. Participants with symptomatic orthostatic hypotension at screening, or who experiences a decrease in systolic blood pressure of ≥ 30 mmHg or a decrease in diastolic blood pressure of ≥ 15 mmHg within 3 minutes when changing from the supine to the standing position (verify before randomization);\n6. Atypical parkinsonian syndromes (such as multiple system atrophy, progressive supranuclear palsy, etc.), or secondary parkinsonism with clearly identified causes such as drug-induced, vascular, toxic, metabolic, infectious, or traumatic brain injury;\n7. Participants who have clinically significant hepatic insufficiency which is defined as the total bilirubin (TBIL) \\> 2 × upper limit of normal (ULN) or alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2 × ULN;\n8. Participants with clinically significant renal insufficiency (creatinine clearance \\[Ccr\\] \\\u003C30 mL\u002Fmin, see Appendix 2 calculation formula);\n9. Any condition (e.g., severe arthritis, severe dyskinesia, traumatic injury with permanent physical disability) that may affect the MDS-UPDRS motor examination;\n10. Participants who have a history of suicidal intention (including actual attempts, interrupted attempts, or failed attempts) and are at risk of committing suicide as judged by the investigator;\n11. Participants judged by the investigator to have severe psychiatric abnormalities (anxiety, depression), with a single item score ≥3 for item 1.3 (Depression) or item 1.4 (Anxiety) in Part 1 of the MDS-UPDRS at screening;\n12. Participants who have taken any serotonin reuptake inhibitors (such as fluoxetine, paroxetine, trazodone, citalopram, escitalopram, etc.) within 4 weeks prior to screening;\n13. Use of anticholinergics or amantadine for PD treatment within 3 months prior to screening, or requiring stable use of anticholinergics or amantadine for PD treatment during the trial;\n14. Participants who have dementia or moderate or above cognitive dysfunction and the MDS-UPDRS score for 1.1 cognitive impairment is ≥ 3 at screening;\n15. Participants who have a history of surgical treatment for PD (e.g., deep brain stimulation, pallidotomy, etc.), or those who have undergone any major or medium surgery or have experienced any serious trauma or serious infection within 3 months prior to screening, those who are unsuitable for this study at the discretion of the investigator or plan to undergo any surgical treatment (excluding an outpatient surgery that has no impact on participant safety or study results as judged by the investigator) during the study;\n16. Participants who have participated in a clinical trial that involves the administration of an investigational drug (a new chemical entity), device, or surgery within 3 months or 5 half-lives before screening, whichever is longer;\n17. Evidence of alcohol abuse (average weekly consumption of ≥14 units of alcohol, where 1 unit ≈ 360 mL of beer, 45 mL of spirits, or 150 mL of wine) or drug abuse within 6 months prior to screening, which in the investigator's opinion would interfere with the participant's understanding or completion of the trial;\n18. Participants who are known to have hypersensitivity\u002Fallergic reaction or intolerance to any component of the investigational product;\n19. Positive for Hepatitis B surface antigen (HBsAg) or positive for Hepatitis B core antibody (HBcAb) with Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) above the upper limit of detection, or positive for Hepatitis C Virus (HCV) antibody, or positive for Human Immunodeficiency Virus (HIV) antibody, or positive for Treponema pallidum antibody at screening;\n20. Pregnant or breastfeeding women;\n21. Participants who are unable to swallow oral drugs, or have any condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or any condition that may pose a hazard to participants participating in the study, as judged by the investigator;\n22. Participants who have a history of organ transplantation (excluding corneal transplantation);\n23. Participants who have donated or lost blood of ≥400 mL, or received blood transfusions within 3 months prior to screening; Participants who have any other conditions that may affect study compliance as deemed by the investigator, or those who are unable to participate in the study for their own reasons.",{"count":191,"type":22},300,[193],"PHASE3","This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients. This study plans to enroll approximately 300 EOPD participants, who will be randomized in a 1:1 ratio to two cohorts (Cohort 1: 200 mg dose group; Cohort 2: 400 mg dose group). Within each cohort, successfully screened participants will be stratified by stable use of dopamine receptor agonists (Yes vs. No) and stable use of Monoamine Oxidase B (MAO-B) inhibitors (Yes vs. No), and within each stratum, randomized in a 2:1 ratio to the TJ0113 Capsules group and the placebo group, with approximately 100 assigned to the TJ0113 Capsules group and approximately 50 assigned to the placebo group. In this trial, the sample size for the TJ0113 Capsules 200 mg group, TJ0113 Capsules 400 mg group, and placebo group will each be approximately 100 participants.\n\nAfter randomization, during the double-blind treatment period, participants will receive continuous oral administration of TJ0113 Capsules or placebo for 26 weeks. After the double-blind treatment ends, participants will enter the open-label treatment period. During the open-label treatment period, all participants will receive oral TJ0113 Capsules for 26 weeks, and the dose of TJ0113 Capsules will be consistent with the dose of the investigational product taken by the participant during the double-blind treatment period (regardless of whether they took TJ0113 Capsules or placebo during the double-blind treatment period). After the open-label treatment period ends, participants will continue to receive a safety follow-up for 1 week (telephone follow-up).\n\nFrom the screening period to the end of the double-blind treatment period, all participants must maintain their original background anti-PD medication regimen unchanged; from the open-label treatment period to the end of the study, changes to the dose of stably received anti-PD medications are discouraged, but if necessary, the dose may be adjusted at the discretion of the investigator.",[28,196],"Parkinson Disease 6, Early-Onset","2026-08-11",{"date":199,"type":37},"2026-08-12",{"date":201,"type":22},"2026-08-03",{"date":203,"type":22},"2028-11-15",{"name":205,"class":154},"Hangzhou PhecdaMed Co., Ltd.",21,{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":106,"sex":17,"minAge":78,"maxAge":19,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":224,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":45},"100625026","lifus-for-neurological-disorders-100625026","NCT07417280","LIFUS For Neurological Disorders","Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders","Inclusion Criteria:\n\n* 18-85 years of age\n* Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)\n* Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders\n\nExclusion Criteria:\n\n* History of stroke\n* Comorbid dementia\n* Scored below 22 on the Montreal Cognitive Assessment (MoCA)\n* Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)\n* Presence of metal implanted in body that is contraindicated in TMS\u002FMRI\n* Pregnancy\n* Major depression\u002Fpsychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study\n* Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol\n* Major systemic illness or infection",{"count":215,"type":22},50,[25],"Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.",[28,219,220,221,222,223,87],"Essential Tremor","Orthostatic Tremor","Dystonia","Epilepsy","Substance Abuse Disorder",[225,219,220,221,222,223,87,226,227,228,229,230,231,232],"Parkinson's Disease","DBS","Substance Use Disorder","SUD","PD","LIFUS","Low-Intensity Focused Ultrasound","Neuromodulation",{"date":175,"type":37},{"date":235,"type":37},"2025-12-02",{"date":237,"type":22},"2040-12-31",{"name":239,"class":44},"University Health Network, Toronto",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":248,"maxAge":79,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100588678","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-bemdaneprocel-in-adults-who-have-parkinsons-disease-100588678","NCT06944522","A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease","exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease","exPDite-2","Inclusion Criteria:\n\n* Diagnosis of clinically established PD as defined by the International Parkinson and Movement Disorders Society\n* Individual of any sex ≥45 to ≤75 years of age at informed consent\n* Robust and clear response to DA therapy as defined by MDS-UPDRS Part III\n* ≥4 and \\\u003C12 years from time of PD diagnosis at informed consent\n* Must demonstrate responsiveness to levodopa therapy\n* Receiving medical therapy for the treatment of PD symptoms\n* ≥2.5 hours of daily OFF-time\n* Vaccinated per current national guidelines or local practice for patients with altered immunocompetence\n\nExclusion Criteria:\n\n* PD presenting with recurrent falls\n* Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis, or clinical features suggestive of a neurodegenerative disease other than PD, including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia\n* Any current or relevant previous history of serious, severe, or unstable physical, neurological, or psychiatric illness that may interfere with study participation, participant's safety, or assessment of endpoints per investigator's judgment\n* History of gene therapy or cell therapy\n* Prior treatment with intrajejunal or subcutaneous infusion therapies for PD\n* Prior surgical or radiation therapy to the brain, including deep brain stimulation (DBS) and lesion therapy, or prior history of intradural spinal cord surgery\n* Contraindication to surgery, general anesthesia, cell therapy, immunosuppression, or other required drugs, or anything that prevents use of PET or MRI\n* Any active infection (including but not limited to HIV, HCV, HBV, CMV, syphilis, or tuberculosis) or condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments\n* Current or previously active malignant disease within the past 5 years\n* Chronic immunosuppressive therapy\n* Receipt of another investigational therapy within 5 half-lives of the active treatment\n* Pregnancy or breastfeeding","45 Years",{"count":250,"type":22},102,[193],"Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).",[85],[246,255,256,257,258],"Cell Therapy","Cellular Therapy","Dopaminergic Neuronal Cell Therapy","Parkinsons Disease",{"date":260,"type":37},"2026-08-04",{"date":262,"type":37},"2025-06-17",{"date":264,"type":22},"2032-03",{"name":266,"class":154},"BlueRock Therapeutics",43,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":45},"100649352","music-therapy-in-parkinsons-disease-100649352","NCT07734181","Music Therapy in Parkinson's Disease","Harmonization of Breathing Through Music Therapy and Its Impact on Anxiety, Quality of Life, and Autonomic Dysfunction in Parkinson's Disease","Inclusion Criteria:\n\n* Parkinson's disease, Hoehn and Yahr stages 1-4\n* good understanding of the German language\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Previous music therapy within the last 12 months\n* Severe hearing impairment\n* Manifest dementia (MoCA \\\u003C 20)\n* Severe physical disability\n* Severe somatic or psychiatric illness\n* Concurrent participation in another clinical trial targeting treatment of Parkinson's disease","79 Years",{"count":215,"type":22},[25],"This study aims to examine whether individual music therapy - involving the slow, gentle bowing of a string instrument, accompanied by the music therapist's singing and lyre playing - can have a relaxing and calming effect on patients with Parkinson's disease and improve anxiety, quality of life, and autonomic dysfunction such as unstable blood pressure.\n\nPeople with Parkinson's disease often struggle with anxiety, apathy, and depression, which can severely affect their quality of life. These symptoms are usually difficult to treat adequately with medication. They are frequently associated with dysfunction of the autonomic nervous system and a reduced variability of heart rate. Both are common in Parkinson's disease and can provide clues about stress and well-being. A healthy heart does not beat at completely regular intervals; instead, the time between beats constantly changes slightly. This fluctuation is called heart rate variability (HRV).\n\nPrimary study outcome will be anxiety. Motivation, depression, individual quality of life, and severity of autonomic symptoms are also assessed using validated questionnaires.\n\nPhysical study measures will be HRV, along with stability of blood pressure, intensity of tremor, ability to walk, and also electroencephalography (EEG) to assess brain activity.\n\nA subproject will explore whether listening to emotionally evocative music can specifically influence the brain in patients with Parkinson's disease (as measured by EEG) and autonomic functions (as measured by HRV). The effectiveness of an emotional response will be measured by a questionnaire (the Geneva Emotional Music Scale).",[28],[116,281,282,283,284,285],"Music therapy","Anthroposophical music therapy","EEG","HRV","Parkinson Anxiety Scale (PAS)","2026-07-29",{"date":288,"type":37},"2026-07-30",{"date":290,"type":37},"2026-06-02",{"date":292,"type":22},"2028-09-02",{"name":294,"class":44},"Siegward -M. Elsas",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":141,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":45},"100649092","efficacy-of-lsvt-loud-therapy-on-voice-speech-and-quality-of-life-in-parkinsons-disease-100649092","NCT07730073","Efficacy of LSVT-LOUD Therapy on Voice, Speech, and Quality of Life in Parkinson's Disease","The Effect of Lee Silverman Voice Therapy-LOUD (LVST-LOUD) Therapy Method on Voice and Speech Skills and Examination of Therapy Experiences in Turkish-Speaking Individuals With Parkinson's Disease","Inclusion Criteria:\n\nDiagnosis: Patients with a confirmed diagnosis of Idiopathic Parkinson's Disease (Hoehn and Yahr stages I-III).\n\nAge: Individuals aged 40-80 years.\n\nLanguage: Native Turkish speakers.\n\nCognitive Status: Sufficient cognitive function to participate in therapy (e.g., Mini-Mental State Examination (MMSE) score ≥ 24).\n\nCommunication: Presence of voice or speech impairment (e.g., hypophonia, reduced intelligibility) as confirmed by a speech-language pathologist.\n\nStability: Stable medication regimen for at least 1 month prior to the study initiation.\n\nExclusion Criteria:\n\nNeurological Comorbidities: Presence of other significant neurological disorders (e.g., stroke, traumatic brain injury, multiple sclerosis) or active voice disorders (e.g., vocal cord nodules, laryngeal cancer).\n\nHearing Impairment: Uncorrected hearing loss that would interfere with speech assessment or therapy.\n\nCognitive Impairment: Diagnosis of dementia or severe cognitive impairment that prevents participation in the intensive LSVT-LOUD protocol.\n\nRecent Surgery: History of laryngeal surgery or deep brain stimulation (DBS) within the last 6 months.\n\nTherapy History: Previous experience with LSVT-LOUD or intensive speech therapy within the past year.",{"count":303,"type":22},24,[25],"Parkinson's disease often causes speech and voice impairments, such as reduced vocal loudness and decreased speech intelligibility, which significantly impact the quality of life for patients and their families. The Lee Silverman Voice Therapy-LOUD (LSVT-LOUD) is a specialized, evidence-based speech therapy protocol designed to improve vocal function.\n\nThis study investigates the effectiveness of the LSVT-LOUD protocol in Turkish-speaking individuals with Parkinson's disease. The research evaluates objective changes in vocal loudness and speech quality, as well as the subjective therapy experiences of participants. By analyzing both clinical outcomes and patient feedback, this study aims to contribute to the clinical application and adaptation of LSVT-LOUD for the Turkish-speaking population",[28],"2026-07-24",{"date":309,"type":37},"2026-07-28",{"date":311,"type":37},"2026-02-18",{"date":313,"type":22},"2027-02",{"name":315,"class":44},"Atlas University",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":341},"100614837","phase-2-a-study-of-buntanetap-in-participants-with-pd-100614837","NCT07284784","A Study of Buntanetap in Participants With PD","An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease","Inclusion Criteria:\n\n1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and\n\n   a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE \\\u003C21 at screening.\n\n   b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.\n\n   i. Female or male adults aged 40 to 85 years. ii. H\\&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.\n2. Have a support person who will accompany the participant on study visits at designated times.\n3. Female participants of childbearing potential\\* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:\n\n   1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,\n   2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,\n   3. Intrauterine device (IUD),\n   4. Intrauterine hormone-releasing system (IUS),\n   5. Bilateral tubal occlusion,\n   6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),\n   7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).\n\n      * Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.\n\n   Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54\n4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:\n\n   1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,\n   2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,\n   3. IUD,\n   4. IUS,\n   5. Bilateral tubal occlusion.\n5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.\n6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.\n\n   1. Standard of care anti-parkinsonian medication,\n   2. Cholinesterase inhibitors and\u002For memantine medication,\n   3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,\n   4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,\n7. Adequate visual and hearing ability (physical ability to perform all the study assessments).\n8. Good general health with no disease expected to interfere with the study.\n\nExclusion Criteria:\n\n1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion\u002Fexclusion criteria).\n2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.\n3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.\n4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.\n5. Bradycardia (\\\u003C50 bpm) or tachycardia (\\>100 bpm) on the ECG at screening and deemed medically significant by the PI.\n\n   Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54\n6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.\n7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] \\\u003C50 mL\u002Fmin\u002FBSA \\[body surface area\\]) or hepatic impairment (Alkaline phosphatase \\[ALP\\] \\> 2.0X the upper limit of normal \\[ULN\\] and\u002For total bilirubin \\> 2.0X ULN).\n8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) greater than twice ULN will be excluded.\n9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.\n10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).\n11. Alcohol \u002F Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.\n12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.\n13. A learning disability or developmental delay.\n14. Participants whom the site PI deems to be otherwise ineligible.\n15. A known allergy to the investigational drug or any of its components.\n\n    Inactive ingredients of the investigational medicinal product:\n    * Silicified microcrystalline cellulose\n    * Dibasic calcium phosphate dihydrate\n    * Mannitol\n    * Stearic acid\n    * Hypromellose (capsule shells structure)\n    * Titanium dioxide (opacifier of the capsule shells)\n16. Is currently pregnant, breast-feeding, and\u002For lactating.\n17. Uncontrolled hypertension (systolic \\>160mmHg and\u002For diastolic \\>95mmHg) or hypotension (systolic \\\u003C90mmHg and\u002For diastolic \\\u003C60 mmHg) and deemed medically significant by the PI.",{"count":324,"type":22},500,[166,193],"This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.",[28,87],[225,229,87,226,329,330,331],"buntanetap","Open-Label","posiphen","2026-07-20",{"date":334,"type":37},"2026-07-21",{"date":336,"type":37},"2026-01-09",{"date":338,"type":22},"2029-11",{"name":340,"class":154},"Annovis Bio Inc.",27,{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":352,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":45},"100648248","phase-1-zr001-chemogenetics-gene-therapy-study-in-patients-with-parkinsons-disease-100648248","NCT07718659","ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease","An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001, a Gene Therapy Based on Chemogenetics, for the Treatment of Parkinson's Disease","Inclusion Criteria:\n\n* Participants who meet all of the following criteria are eligible for enrollment:\n\n  1. Age ≥40 and ≤70 years (at the time of signing the informed consent), any gender.\n  2. Diagnosed with Parkinson's disease according to the Diagnostic Criteria for Parkinson's Disease in China (2016 edition).\n  3. Modified Hoehn \\& Yahr stage between 2.5 and 4.\n  4. History of Parkinson's disease for at least 5 years but less than 15 years.\n  5. Moderate to severe MDS-UPDRS Part III score in the off period, and improvement rate ≥30% after acute levodopa stress test.\n  6. Clinically stable symptoms and stable types and doses of anti-Parkinsonian medications within 3 months prior to enrollment.\n  7. Agree to provide biological samples required for the study (e.g., blood, urine).\n  8. Consent to hospitalization for intraparenchymal drug injection surgery.\n  9. Male or female participants of childbearing potential agree to use effective contraceptive methods (oral contraceptives are prohibited) from the time of signing the informed consent until at least 6 months after discontinuing clozapine.\n  10. Participants or their stable caregivers are able to understand and willing to comply with the study requirements and procedures, voluntarily participate, and sign the informed consent. If a caregiver is present, they must accompany the participant to study visits and assist the investigator in completing relevant scale assessments.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria will be excluded from this study:\n\n  1. Have participated in or are currently participating in other clinical studies of PD drugs or other AAV gene therapy or cell therapy.\n  2. Presence of other severe psychiatric disorders (e.g., severe depression, schizophrenia, etc.).\n  3. Previous adverse reactions to clozapine, such as agranulocytosis or severe neutropenia.\n  4. Participants with known allergic constitution, including allergy or hypersensitivity to clozapine, prednisone acetate, other glucocorticoids, their excipients, or local anesthetics.\n  5. History of alcohol or drug abuse within the past 2 years.\n  6. Participants requiring invasive or non-invasive ventilatory support.\n  7. Serum AAV binding antibody titer \\>1:2000.\n  8. Presence of clinically significant laboratory abnormalities as assessed by the investigator: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin; creatinine, hemoglobin (Hb), prothrombin time (PT), activated partial thromboplastin time (APTT), fasting blood glucose, platelets (PLT).\n  9. Presence of liver disease, heart disease, kidney disease or history thereof, which, in the investigator's assessment, may pose surgical or drug-related risks to the participant.\n  10. Suffering from autoimmune diseases or immunocompromised status requiring hormone or immunosuppressive therapy, which, in the investigator's assessment, may pose surgical or drug-related risks.\n  11. Suffering from other severe systemic diseases (e.g., cor pulmonale, moderate-to-severe asthma, etc.) that, in the investigator's assessment, may pose surgical or drug-related risks.\n  12. In the investigator's assessment, the participant has contraindications to anesthesia or surgery and is unsuitable for intraparenchymal administration, or other special circumstances.\n  13. Positive for human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, active TORCH virus infection, or active Epstein-Barr virus infection.\n  14. Concomitant use of any of the following medications within 90 days prior to administration, or planned immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab) within 6 months after start of the trial, except for prophylactic medications specified in the protocol.\n  15. Pregnant or breastfeeding women, or those planning to become pregnant.\n  16. Other conditions that, in the investigator's opinion, make the participant unsuitable for participation in this study.","70 Years",{"count":351,"type":22},8,[110],"This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra, followed by postoperative ultra-low-dose clozapine to activate the transduced direct pathway, with the goal of improving motor symptoms of Parkinson's disease.",[28,355],"Parkinsonian Disorders",[357,358,229,359,360,361,225,362,363,364,365],"AAV","DREADD","D1-MSN","Gene Therapy","Chemogenetics","Clozapine","Central Nervous System Diseases","Movement Disorders","Neurodegenerative Diseases","2026-07-17",{"date":368,"type":37},"2026-07-22",{"date":370,"type":22},"2026-12-01",{"date":372,"type":22},"2030-12-01",{"name":374,"class":44},"Qianfoshan Hospital",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":141,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":45},"100639756","phase-2-the-efficacy-of-psilocybin-therapy-for-depression-in-parkinsons-disease-100639756","NCT07610369","The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","PSI-PD","Inclusion Criteria:\n\n* Able to understand and provide informed consent\n* Comfortable speaking and writing in English\n* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an \"on\" phase (time when medication\u002FDBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)\n* Have no changes in medication or major surgical procedures anticipated for treatment duration\n* Have a score \\>\u002F=20 on the Beck Depression Inventory-2 (BDI-2), consistent with moderate or greater depressive symptom severity, at Baseline.\n* For people who can become pregnant: agree to use highly effective contraception from entry into the trial through Day B30 assessments (4 weeks after the second psilocybin administration session) and agree to not breastfeed. Acceptable methods of contraception are: An intrauterine device (IUD), hormone-based contraceptives (birth control pills) , condoms (internal or external) must be used with another method (other than spermicide), and complete abstinence from sexual activity that could result in pregnancy.\n* Agree that for one week preceding each psilocybin session, they will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the research team. Exceptions will be evaluated by the research team and assessed for safety. Agree to abstain from all tobacco and nicotine use for the duration of the study.\n* Agree to consume approximately the same amount of caffeine-containing beverages that they usually consume before arriving at the research unit on the mornings of psilocybin administration sessions.\n* Agree to avoid sedative-hypnotic medications (e.g., benzodiazepines, zolpidem, zopiclone, zaleplon) taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session.\n* Agree to avoid opioid medications taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session.\n* Agree not to use products or substances containing Δ9-tetrahydrocannabinol (THC) and\u002For cannabidiol for at least 7 days prior to each psilocybin administration session and for 24 hours after each psilocybin administration session.\n* Agree to not use non-prescribed narcotics (eg. heroine, fentanyl), depressants (eg. Barbiturates, benzodiazepines) and\u002For inhalants for the duration of participation in the trial.\n* Agree not to consume alcoholic beverages for at least 24 hours prior to and 24 hours following each psilocybin administration session.\n* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating care and is available for consultation with the study medical monitor.\n\nExclusion Criteria:\n\n* Any indication of forms of parkinsonism other than idiopathic Parkinson's disease.\n* Cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \\\u003C24.\n* Symptomatic orthostatic hypotension.\n* Currently receiving electroconvulsive therapy (ECT) or treatment via transcranial magnetic stimulation (TMS). Previous treatment with ECT and\u002For TMS is permitted; last treatment must be at least 30 days prior to entry into this trial.\n* Treatment in a clinical trial within 30 days of entry into this trial or treatment with another investigational drug or other intervention within 30 days or 5 half-lives, whichever is longer, prior to entry into this trial.\n* Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial.\n* Current severity of psychiatric symptoms warranting immediate treatment as determined by the study medical staff (e.g. due to inability to provide for basic needs\u002Fsafety). The study medical staff will assess these individuals, determine the appropriate level of care, and coordinate with the individual's primary providers to ensure close follow-up.\n* High risk of self-harm\u002Fsuicide, as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) risk screen, specifically: participant answers \"yes\" to item 4 or 5 suggesting intent to act on suicidal thoughts OR participant has made a serious suicide attempt within the 12 months prior to entry into this trial.\n* History of meeting DSM-5 criteria for a schizophrenia spectrum disorder, other psychotic disorder, or a mood disorder with psychotic features.\n* History of delusional symptoms or any other psychotic symptoms accompanied by a loss of insight. Exceptions may be made at the investigators' discretion in cases of a history of psychotic symptoms that were attributable to substance or medication use.\n* Current delusional symptoms or any other psychotic symptoms accompanied by a loss of insight.\n* History of a schizophrenia spectrum disorder in a first-degree relative.\n* History of bipolar disorder 1 in a first-degree relative, in whom illness onset was prior to age 40.\n* Current or history of meeting DSM-5 criteria for a bipolar disorder.\n* Current or history within the last 2 years of meeting DSM-5 criteria for a moderate or severe alcohol or drug use disorder, excluding caffeine.\n* Currently meeting DSM-5 criteria for another psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin treatment procedures as determined by the investigators.\n* History of meeting DSM-5 criteria for Hallucinogen Persisting Perception Disorder (HPPD).\n* History of using any psychedelic substances including psilocybin, lysergic acid diethylamide (LSD), mescaline (and natural products containing mescaline including peyote and San Pedro cactus), N,N-Dimethyltryptamine (DMT), natural products containing DMT including ayahuasca and 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine, 2C compounds, 3,4-methylenedioxy-methamphetamine (MDMA), or methylone during the past 6 months at dosages and\u002For frequencies determined clinically significant by the investigators.\n* Cancer with known central nervous system (CNS) involvement, CNS infection, or other major CNS disease aside from PD.\n* Epilepsy or other seizure disorder in adulthood.\n* Supplemental oxygen requirement.\n* Allergy or intolerance to any of the materials contained in the drug products.\n* Renal insufficiency defined as creatinine clearance \\\u003C 40 ml\u002Fmin using Cockraft and Gault equation\n* Insufficiently managed endocrine conditions, including diabetes mellitus and clinically significant thyroid dysfunction.\n* Cardiovascular conditions, including:\n\n  * Elevated blood pressure defined as systolic blood pressure (SBP) \\>150 or diastolic blood pressure (DBP) \\>95 taken during Enrollment\n  * Tachycardia defined as heart rate (HR) \\>90 beats per minute taken during Enrollment\n  * Bradycardia defined as HR \\\u003C50 bpm taken during Enrollment\n  * Angina\n  * History of stroke within the past year\n  * Clinically significant ECG abnormality as determined by the investigators, including but not limited to QTc \\> 450\n* Hepatic dysfunction as indicated by any of the following laboratory values:\n\n  * AST \\> 3 x upper limit of normal\n  * ALT \\> 3 x upper limit of normal\n  * Total bilirubin \\> 3.0 mg\u002Fdl\n* Use of any of the following concomitant medications AND inability\u002Funwillingness to discontinue for at least 5 times the elimination half-life of the agent (specific exceptions are noted) prior to psilocybin administration, including:\n\n  * Agents that may be associated with serotonin syndrome:\n\n    * MAO inhibitors (participants must have discontinued 2 weeks prior to baseline)\n    * St. John's Wort\n    * S-adenosyl-methionine (SAM-e)\n    * 5-Hydroxytryptophan (5-HTP)\n    * Dextromethorphan\n    * Opioids (e.g., codeine, fentanyl, hydrocodone, meperidine, tramadol)\n    * Lithium\n    * Linezolid\n    * Buspirone\n  * Agents that may interact with psilocybin metabolism\u002Feffects:\n\n    * Serotonin antagonists (e.g., cyclobenzaprine, ondansetron)\n    * Antipsychotics\n    * Other dopamine antagonists (e.g., metoclopramide, promethazine, prochlorperazine)\n    * Nicotine\n    * Modulators of uridine diphosphate (UDP) or glucuronosyltransferase (UGT) (e.g. valproate, diclofenac, mefenamic acid, verapamil, ketoconazole, itraconazole, probenecid, phenobarbital, protease inhibitors)\n    * L-methyl folate (\\>\u002F= 7.5mg\u002Fday)\n    * Efavirenz\n  * Agents that may increase the risk of psychotic symptoms:\n\n    * Stimulants (e.g. modafinil, methylphenidate, atomoxetine, methamphetamine, cocaine, amphetamine derivatives)\n    * Anticholinergics (e.g. benztropine, trihexyphenidyl, scopolamine, hyoscyamine)\n    * Systemic steroids\n  * Tricyclic antidepressants\n* Other medical condition or diagnosis, concomitant medication(s), physical exam finding, laboratory abnormality or health risk identified that precludes participation in study procedures due to safety or feasibility concerns at the discretion of the investigators.",{"count":383,"type":22},40,[166],"The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.",[387,28],"Depression",[389,387,390,391,392],"Parkinson's Diesease","Psilocybin","Psilocybin therapy","Movement disorder","2026-07-16",{"date":332,"type":37},{"date":396,"type":22},"2026-07",{"date":398,"type":22},"2030-07",{"name":400,"class":44},"Yale University",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":420,"leadSponsor":422,"locationsCount":4},"100647870","a-study-of-dimdazenil-in-patients-with-parkinsons-disease-and-insomnia-100647870","NCT07714772","A Study of Dimdazenil in Patients With Parkinson's Disease and Insomnia","Efficacy and Safety of Dimdazenil, a GABAA Receptor Partial Agonist, in the Treatment of Insomnia in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Provide written informed consent voluntarily after full comprehension of the study.\n* Be aged ≥18 years, male or female.\n* Meet the diagnostic criteria for Parkinson's disease according to the Chinese Diagnostic Criteria for Parkinson's Disease (2016 Edition), with a modified Hoehn-Yahr stage ≤3.\n* Have insomnia symptoms \\[reduced total sleep time (\\\u003C6.5 h) and\u002For sleep-onset latency \\>30 min, and\u002For ≥2 nocturnal awakenings, early-morning awakening, or poor sleep quality\\], occurring at least three times per week, accompanied by daytime dysfunction or daytime distress, with adequate opportunity for sleep yet difficulty initiating or maintaining sleep, and that cannot be fully explained by another sleep-wake disorder; and have satisfactory control of Parkinson's disease motor symptoms \\[MDS-UPDRS Part III (ON state) score ≤30\\].\n* Be on a stable anti-Parkinsonian medication regimen, defined as no change in the type, dosage, or frequency of anti-Parkinsonian drugs for at least 4 weeks prior to enrollment, with no motor fluctuations or dyskinesia.\n* Have a clinical decision by the attending physician to initiate didazinin treatment per routine practice.\n* Be able to undergo polysomnography (PSG) monitoring.\n* Be conscious, capable of normal communication, and able to complete sleep diaries independently.\n\nExclusion Criteria:\n\n* Have Parkinson-plus syndromes, secondary parkinsonism, or other non-idiopathic Parkinson's disease.\n* Have used benzodiazepine sedative-hypnotics within 7 days prior to enrollment.\n* Have other significant comorbidities, such as malignant tumors, or clinically significant impairment of cardiac, hepatic, or renal function.\n* Have severe obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), respiratory insufficiency, or myasthenia gravis.\n* Have known hypersensitivity to any component of didazinin.\n* Have moderate-to-severe depression or anxiety, defined as a Hamilton Depression Rating Scale (HAMD) score ≥25 or a Hamilton Anxiety Rating Scale (HAMA) score ≥29.\n* Have a history of substance abuse (e.g., drug addiction or alcohol dependence).\n* Have a history of epilepsy, schizophrenia, bipolar disorder, developmental delay, or cognitive impairment.\n* Be pregnant or breastfeeding.\n* Be unwilling or unable to comply with scheduled follow-up visits.\n* Have any other condition that, in the investigator's judgment, would make the subject unsuitable for participation (e.g., anticipated inability to complete follow-up within 14 days, or concurrent use of other medications that may substantially interfere with sleep assessment and cannot be withdrawn).",{"count":215,"type":22},"This study will use sleep parameters measured by polysomnography (PSG) as the primary means to evaluate the efficacy and safety of dimdazenil, a GABAA receptor partial agonist, in treating insomnia in Parkinson's disease patients.",[411,28],"Insomnia",[411,116,413,414,415,416],"Daytime Function","effective","safety","dimdazenil","2026-07-15",{"date":332,"type":37},{"date":94,"type":22},{"date":421,"type":22},"2026-12-31",{"name":423,"class":44},"Second Affiliated Hospital of Soochow University",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":431,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100619088","phase-1-coordinated-reset-deep-brain-stimulation-for-parkinsons-disease-100619088","NCT07340073","Coordinated Reset Deep Brain Stimulation for Parkinson's Disease","CR DBS PD","Inclusion Criteria:\n\n* Diagnosis of Idiopathic Parkinson's Disease\n* Minimum age of 21 years old\n* Will be or has been implanted with the Boston Scientific Vercise Genus Rechargeable DBS system\n\nExclusion Criteria:\n\n* History of musculoskeletal disorders that affect movement of the limbs\u002Fgait\n* Other significant neurological disorder\n* Significant psychiatric disorder\n* History of dementia or cognitive impairment that precludes them from getting DBS surgery or per study staff judgment, MacCAT-CR assessment does not deduce that the participant has capacity to consent\n* Other significant medical disorder that could impede study participation\n* Pregnant women","21 Years",{"count":303,"type":22},[110],"Deep brain stimulation (DBS) is a surgical implant procedure for the treatment of Parkinson's Disease (PD) utilizing medical devices approved by the FDA. A novel approach to current DBS approaches is called \"Coordinated Reset\" DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude and high frequency stimulation. This study will evaluate the safety and short-term efficacy of CR-DBS in PD. The results from this study will significantly advance the development of CR-DBS for the treatment of PD. Findings in this study will also provide the rationale for further development of this novel DBS approach for other neurological and psychiatric disorders.",[28,87],[437,225],"Deep Brain Simulation","2026-07-08",{"date":440,"type":37},"2026-07-10",{"date":442,"type":22},"2026-09-01",{"date":444,"type":22},"2031-07-01",{"name":446,"class":44},"University of Minnesota",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":106,"sex":17,"minAge":78,"maxAge":275,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":457,"briefSummary":458,"conditions":459,"keywords":462,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":45},"100645895","moving-yourself-in-space-and-time-mystic-100645895","NCT07697664","Moving Yourself in Space and Time: MYSTIC","Moving Yourself in Space and Time Identifying Spatial and Temporal Components of Complex Rhythmic Movement Training for People With Parkinson's Disease and Cognitive Impairment","MYSTIC","Inclusion Criteria for Young adults and adults with normal cognition (NC):\n\n* 18 to 35 Years old\n* Montreal Cognitive Assessment (MoCA) score of 26 to 30\n\nInclusion Criteria for Older Adults:\n\n* 50 to 79 with or without MCI\n* 50 to 79 years old with Parkinson's disease (PD), who do NOT have impaired decision-making capacity\n* Participants who achieve less than 150 minutes moderate or 75 minutes vigorous aerobic activity per week (as per the US Department of Health and Human Services (HHS)),\n\nExclusion Criteria for all groups:\n\n* Acute medical illness requiring hospitalization;\n* Uncontrolled congestive heart failure;\n* History of stroke in the past three years;\n* Inability to perform study procedures;\n* Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity);\n* On medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, and neurologic prescriptions to treat Multiple Sclerosis. When applicable, enrollment will be delayed until dosages are stable on e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months\n* Psychotic disorders\n* Confounding neurologic conditions \\[e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness \\>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae\\]\n* Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorder within six months of evaluation.\n* Inability to provide informed consent",{"count":456,"type":22},210,[25],"This study is being done to answer the question: Do people with Parkinson's benefit from a new stepping therapy, and how do people with Parkinson's best learn new steps and rhythms set to music? Researchers will also compare individuals with Parkinson's Disease with people with Mild Cognitive Impairment, and with people with neither of these conditions.\n\nThe purpose of this study is to identify principles of human-music interactions to establish underlying guiding theories for application to music-based rehabilitation for older populations with neurodegenerative disease, leading to more refined and targeted music-based rhythmic movement therapies.",[28,460,461],"Alzheimer's Disease (AD) and Related Disorders","Older Adults (60 - 85 Years Old)",[463,464,465,466,467,468,469,470,471],"Dance","Music","Therapy","Rehabilitation","Neurodegenerative","Parkinson's","Alzheimer's","Motor learning","Motor control","2026-07-07",{"date":474,"type":37},"2026-07-13",{"date":476,"type":37},"2022-03-25",{"date":478,"type":22},"2028-12",{"name":480,"class":44},"Emory University",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":141,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":45},"100645521","directional-psa-versus-stn-dbs-for-td-pd-100645521","NCT07700862","Directional PSA Versus STN DBS for TD-PD","Directional Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial","Inclusion Criteria:\n\n* diagnosis of idiopathic Parkinson's disease\n* tremor-dominant subtype in the off-medication condition\n* modified Hoehn-Yahr scale of 2 to 4 in the off-medication condition\n* receiving regular anti-parkinsonian drugs for more than 6 weeks\n* good compliance and written informed consent provided\n\nExclusion Criteria:\n\n* Atypical parkinsonism\n* History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery\n* Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent\n* Presence of anatomical abnormalities in the target region\n* Clinically significant medical history that would increase pre-\u002Fpost-operative complications\n* Other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data",{"count":489,"type":22},32,[25],"The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.",[85],[494,495,496,497],"tremor-dominant Parkinson's disease","directional deep brain stimulation","posterior subthalamic area","subthalamic nucleus",{"date":499,"type":37},"2026-07-14",{"date":501,"type":37},"2026-07-01",{"date":503,"type":22},"2029-06",{"name":43,"class":44},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":513,"maxAge":141,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":521,"leadSponsor":523,"locationsCount":4},"100645363","lrrk2-leucine-rich-repeat-kinase-2-parkinsons-disease-fingerprint-100645363","NCT07681219","LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint","LRRK2 Associated Parkinson's Disease: Definition of a Clinical, Molecular and Neurophysiological Fingerprint","NEU-PD","Inclusion Criteria:\n\n* age 30-80 years,\n* clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,\n* Hoehn \\& Yahr (H\\&Y) stage between 1 and 3,\n* 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,\n* ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active or history of other neurological disorders,\n* active infectious disease or history within the previous 4 weeks,\n* continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,\n* active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;\n* alcohol or drug abuse or dependence\n* any contraindication to the execution of the MRI (including claustrophobia).","30 Years",{"count":81,"type":22},[25],"The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study",[85,518],"LRRK2",{"date":440,"type":37},{"date":442,"type":22},{"date":522,"type":22},"2029-09-01",{"name":524,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":543,"leadSponsor":545,"locationsCount":45},"100641196","the-effects-of-tele-rehabilitation-based-dual-task-upper-extremity-training-in-patients-with-parkinsons-disease-100641196","NCT07641556","The Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease","Investigating the Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Having been diagnosed with Parkinson's disease by a neurologist according to the UK Brain Bank criteria\n* Being in stage 3 or higher according to the Hoehn-Yahr Scale\n* Having a caregiver capable of providing the necessary assistance during tele-rehabilitation sessions and using the required equipment and programs.\n* Having the device and software to conduct remote video calls for tele-rehabilitation\n\nExclusion Criteria:\n\n* Presence of a neurological disease other than Parkinson's disease\n* Cognitive impairment (Standardized Mini Mental Test score less than 24)\n* Having undergone deep brain stimulation surgery\n* Having a visual, auditory, or perceptual problem\n* Having any orthopedic, rheumatological, or other condition that may affect hand functions",{"count":383,"type":22},[25],"The aim of this study is to compare the effects of tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training with clinical based dual-task upper extremity training and conventional single-task upper extremity training in patients with Parkinson's disease. The main questions it aims to answer are:\n\n* Whether there are differences in motor symptoms, hand dexterity, upper extremity functions, grip strength, executive functions, daily living activities, and treatment satisfaction between tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training, clinical-based dual-task upper extremity training, and conventional single-task upper extremity training in patients with Parkinson's disease.\n* Whether there is a difference in telemedicine satisfaction between tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training in patients with Parkinson's disease.\n\nResearchers will compare conventional single-task upper extremity training, clinical-based dual-task upper extremity training, tele-rehabilitation-based synchronous upper extremity training and tele-rehabilitation-based asynchronous upper extremity training.\n\nParticipants will:\n\n* Receive upper extremity exercise training at the study clinic or home, twice a week for approximately 60 minutes each time, for 6 weeks.\n* Participate in assessments at the study clinic before and after exercise training.",[28],[225,537,538,539],"Dual Task Training","Upper Extremity","Tele-Rehabilitation","2026-07-02",{"date":472,"type":37},{"date":501,"type":37},{"date":544,"type":22},"2026-09-15",{"name":546,"class":44},"Saglik Bilimleri Universitesi",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":79,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":568,"leadSponsor":570,"locationsCount":572},"100642015","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-energi-f705-tablets-for-parkinsons-disease-100642015","NCT07647614","A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease","A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease","Inclusion Criteria:\n\nA subject is eligible for the study if all of the following apply:\n\n1. With either gender aged ≥ 40 to ≤ 75 years old at Visit 1 (Screening Visit)\n2. Has been diagnosed with idiopathic Parkinson's disease (defined by the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's disease) for ≥ 2 years prior to or at Visit 2 (Day 1)\n3. Has a modified Hoehn and Yahr stage of 2 to 3 while assessed in the medication-off state at Visit 1 (Screening Visit)\n4. With MDS-UPDRS Part III (motor examination) score of 15 to 60 while assessed in the medication-off state at Visit 1 (Screening Visit)\n5. Without motor complications, which is defined as a score of 2 or less on the MDS-UPDRS Part IV score at Visit 1 (Screening Visit)\n6. Has received a stable standard-of-care regimen, as determined by the investigator, during the 12 weeks prior to Visit 2 (Day 1) and is currently on the following antiparkinsonian medications with an average levodopa equivalent daily dose (LEDD) of ≥ 300 mg during the same period, including:\n\n   * Levodopa\n   * Catechol-O-methyl transferase (COMT) inhibitors\n   * Monoamine Oxidase-B (MAO-B) inhibitors\n   * Ergot-derived dopamine receptor agonists\n   * Non ergot-derived dopamine receptor agonists\n   * Others with established levodopa-conversion factors\n7. Has adequate indices as follows at Visit 1 (Screening Visit):\n\n   * Hematology: white blood cells (WBC) should be ≥ 3,000 cells\u002FμL, platelet count should be ≥ 80,000 per μL of blood\n   * Coagulation: prothrombin time, international normalized ratio (INR), and activated partial thromboplastin time (APTT), all of which should be ≤ 1.5 times the upper limit of the normal range (ULN)\n   * Liver function: serum total bilirubin should be ≤ 1.5 times ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) should be ≤ 3 times ULN\n   * Renal function: an estimated glomerular filtration rate (eGFR) should be ≥ 60 mL\u002Fmin\u002F1.73m2, calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation\n8. Is willing and able to comply with all required study visits and follow-ups required by this protocol\n9. Understands the study procedures and provided written informed consent (including through use of a legally authorized representative, if necessary)\n10. Is able to complete all subject-reported outcome measures\n\nExclusion Criteria:\n\nAny subject meeting any of the exclusion criteria will be excluded from study participation:\n\n1. Has been diagnosed with atypical Parkinson's disease or secondary parkinsonism\n2. Has any of the following neurosurgical intervention for Parkinson's disease within 2 years prior to or at Visit 2 (Day 1):\n\n   * Deep brain stimulation\n   * Pallidotomy\n   * Thalamotomy\n   * Other procedures that may affect motor function\n3. With Mini-Mental State Examination (MMSE) score of \\\u003C 24 at Visit 1 (Screening Visit)\n4. With a lifetime history of significant psychiatric disorder (e.g., alcohol use disorder, drug abuse, or suicide attempt), which in the investigator's opinion, may interfere with study participation\n5. With history of malignancy or current malignancy within 2 years prior to or at Visit 2 (Day 1)\n6. With ongoing or a documented history of within 2 years prior to or at Visit 2 (Day 1) of acute diseases or severe medical conditions, including:\n\n   * Cardiovascular (myocardial infarction, congestive heart failure, New York Heart Association Grade III or IV)\n   * Pulmonary (severe chronic obstructive pulmonary disease, pulmonary hypertension, or other clinically significant respiratory conditions)\n   * Current severe infections, medical history, physical examination findings, or laboratory examination abnormality that in the investigators' opinion are not in stable condition and participating in the study could interfere with the results of the trial or adversely affect the safety of the subject\n7. Administered dopamine-blocking agents within 12 weeks prior to or at Visit 2 (Day 1), including:\n\n   * Typical antipsychotics (e.g., Haloperidol, Chlorpromazine)\n   * Atypical antipsychotics (e.g., Risperidone, Quetiapine or Clozapine)\n8. With clinically significant gastrointestinal disorders that may affect oral drug absorption or tolerability (e.g., inflammatory bowel disease within 12 weeks prior to or at Visit 2 (Day 1) or relevant gastrointestinal surgery recorded on a lifetime basis)\n9. With a history of gout or urolithiasis, or treatment with medications for gout or urolithiasis, within 2 years prior to or at Visit 2 (Day 1)\n10. With known hypersensitivity to any component of the investigational product\n11. Has participated in another clinical trial involving an investigational product, medical device, or surgical procedure within 4 weeks prior to Visit 1 (Screening Visit)\n\n    \\* Note: Subjects enrolled in non-interventional clinical trials will be eligible.\n12. Female subject with childbearing potential who is lactating or has positive serum or urine pregnancy test at Visit 2 (Day 1)\n\n    \\* Note: Female subjects with any of following conditions are considered not with childbearing potential\n    * With menopause ≥ 1 year\n    * Prior surgical procedures resulting in infertility\n    * Documented follicle-stimulating hormone or luteinizing hormone levels consistent with postmenopausal status\n13. Female subjects with childbearing potential or male subjects with partners of childbearing potential who refuse to use highly effective contraceptives from signing informed consent until the end of study (EOS) or early termination (ET) visit\n\n    \\* Note: At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:\n    * Established use of oral, injected or implanted hormonal methods of contraception\n    * Placement of an intrauterine device (IUD) or intrauterine system (IUS)\n    * Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical\u002Fvault caps)\n14. Is an employee of the investigator's site, the sponsor, or its delegate (e.g., contract research organization) who is directly involved in the conduct of the study",{"count":555,"type":22},105,[166],"The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is:\n\nDoes ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment?\n\nInvestigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease.\n\nParticipants will:\n\n* Take the study drugs twice a day for 72 weeks in the treatment group\n* Take routine use of standard-of-care antiparkinsonian medications throughout the study\n* Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests",[28],[560,561,562,563,564],"Phase II","Randomized","Double blind","ENERGI","Parkinson' disease","2026-06-30",{"date":540,"type":37},{"date":370,"type":22},{"date":569,"type":22},"2030-01-01",{"name":571,"class":154},"Energenesis Biomedical Co., Ltd.",2,{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":513,"maxAge":349,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":592,"leadSponsor":594,"locationsCount":45},"100646986","early-phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-efficacy-of-intracerebral-injection-of-ly-n001-injection-for-the-treatment-of-moderate-to-advanced-parkinsons-disease-with-gba1-mutations-100646986","NCT07685444","A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations","A Prospective, Single-Arm, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Administration of LY-N001 Injection in Subjects With Moderate to Advanced Parkinson's Disease Carrying GBA1 Mutations","Inclusion Criteria:\n\n1. Aged 30 to 70 years inclusive; both males and females are eligible.\n2. The participant fully understands the purpose, nature, procedures of the study and potential adverse events, voluntarily agrees to take part in the study and signs the informed consent form (ICF).\n3. Participants with clinically diagnosed idiopathic Parkinson's disease (PD) meeting the 2015 Movement Disorder Society (MDS) diagnostic criteria for idiopathic PD.\n4. Participants carrying at least one pathogenic GBA1 variant.\n5. Duration of PD disease ≥ 3 years.\n6. Off-state Hoehn-Yahr stage ranges from 2.5 to 4.\n7. Neutralizing antibody titer against AAV ≤ 1:200.\n8. The off-state MDS-UPDRS Part III (see Appendix 6 for MDS-UPDRS Part III motor examination) score is greater than 25, with either a ≥30% improvement rate on the acute levodopa challenge test, or an average daily off time of ≥2.5 hours over 3 consecutive days.\n9. Investigators determined that patients must receive a stable dose of dopaminergic medications, including levodopa, for a minimum of 4 weeks prior to surgery.\n10. Acceptable laboratory test values shall be obtained during the screening period and prior to administration (Day -3)：a).Hemoglobin ≥ 100 g\u002FL; b).Platelets ≥ 100 × 10⁹\u002FL; c). Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN); d).Total bilirubin ≤ 2 × upper limit of normal (ULN); e).Estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin.\n11. Demonstrates good treatment adherence and ability to attend scheduled follow-up visits; the participant shall be capable of accurately completing the Parkinson's disease (PD) diary during follow-up, or the participant's family member, legal guardian or caregiver may assist with diary completion.\n12. The participant agrees to postpone any other planned elective neurosurgical procedures (excluding emergent life-threatening neurosurgical operations occurring during the study), including Deep Brain Stimulation (DBS), until completion of the 52-week follow-up period, unless DBS treatment is recommended by a specialist in the participant's best interest.\n13. The participant agrees not to participate in any other therapeutic intervention studies during the study period and shall not take any other medications that may interfere with treatment other than those specified in the protocol.\n14. The participant agrees to refrain from receiving any vaccinations within 30 days after surgery.\n15. The participant must be willing to refrain from donating blood, organs, tissues or cells at any time following treatment administration.\n16. Female participants of childbearing potential (WOCBP) must have a negative pregnancy test.\n17. The participant and their partner have no plans to conceive from screening through 6 months after study completion, and will voluntarily use effective contraceptive measures (such as abstinence, condoms, etc.); the participant has no intention to donate sperm or ova.\n\nExclusion Criteria:\n\n1. Atypical or secondary parkinsonism (including Parkinson-plus syndromes, hereditary parkinsonism, drug-induced parkinsonism, etc.).\n2. Patients with clinically confirmed LRRK2 mutation.\n3. Previous history of pallidotomy, Deep Brain Stimulation (DBS) surgery, striatal surgery, extrapyramidal surgery, stereotactic brain surgery or other brain surgeries; or any other surgical history judged by the investigators to interfere with the subject's participation in this study.\n4. Participants with previous head Computed Tomography (CT) \u002F Magnetic Resonance Imaging (MRI) showing neurological diseases such as brain trauma, vascular malformations, hydrocephalus, brain tumors; subjects with hyperintense white matter signals on MRI indicating risk of intracranial hemorrhage; subjects with cerebrovascular lesions or microbleeds on SWI (Susceptibility-Weighted Imaging); subjects with vulnerable plaques or intraplaque hemorrhage of craniocervical arteries on HR-MRI (High-Resolution Magnetic Resonance Imaging); or subjects with imaging abnormalities in the striatum or other brain regions that substantially increase surgical risks.\n5. The participant has a Mini-Mental State Examination (MMSE) score of less than 20.\n6. A Patient Health Questionnaire (PHQ) score of ≥16 indicates severe depression.\n7. Any severe psychiatric illnesses including epilepsy, severe anxiety, schizophrenia that are deemed unsuitable for participation in this study by the investigators, excluding mild hallucinations and similar symptoms induced by anti-Parkinsonian medications.\n8. Patients taking anticoagulants or antiplatelet drugs whose coagulation function has not returned to normal 10 days after drug discontinuation.\n9. Patients who have previously received gene therapy or cell therapy.\n10. Use of systemic glucocorticoids or immunosuppressive drugs within 12 weeks prior to administration, except for prophylactic immunosuppressive agents required by the protocol (excluding prophylactic immunosuppressive therapy specified in the protocol).\n11. Participants with unstable cardiovascular and cerebrovascular diseases, defined as clinical cardiovascular and cerebrovascular events occurring within 3 months prior to screening (e.g., unstable angina, myocardial infarction, stroke, etc.); uncontrolled diabetes mellitus with glycated hemoglobin \\>8.0%; or other unstable acute or chronic diseases including infectious diseases, severe uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg), or severe orthostatic hypotension (a drop in systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg within 3 minutes after the participant changes from supine\u002Fsquatting position to standing position).\n12. Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA); positive Hepatitis C Virus antibody (HCV-Ab) or Hepatitis C Virus Ribonucleic Acid (HCV-RNA).For participants with a prior history of hepatitis B or hepatitis C, two samples collected at an interval of at least 3 months must test negative for all above indicators to be considered negative. Participants with spontaneously cleared or antivirally treated cleared hepatitis B or C are eligible for this study.Participants with positive Human Immunodeficiency Virus (HIV) test or positive syphilis serology.\n13. Participants with surgical contraindications, those who have received other surgical procedures deemed to interfere with this study by the investigators within six months, or those with other contraindications to neurosurgery.\n14. Participants with an average weekly alcohol intake exceeding 21 units for males or 14 units for females within 30 days prior to screening; 1 alcohol unit equals one 5 oz (150 mL) glass of red wine, 12 oz (360 mL) beer, or 1.5 oz (45 mL) distilled spirits; or participants with a history of drug dependence.\n15. Participants with contrast medium allergy who cannot undergo MRI, or those unable to tolerate surgical anesthesia.\n16. Participants with hypersensitivity to LY-N001 Injection.\n17. History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer, fully cured carcinoma in situ, and papillary thyroid carcinoma cured after radical surgical resection.\n18. Pregnant women, women planning pregnancy, or breastfeeding women.\n19. Participants who are currently enrolled in another clinical trial, or those who participated in another clinical trial and received investigational products within one month.\n20. Participants who are deemed ineligible for enrollment upon investigator's assessment.",{"count":133,"type":22},[582],"EARLY_PHASE1","This is a prospective, single-arm, single-dose clinical study designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-N001 Injection in patients with moderate-to-advanced Parkinson's disease carrying GBA1 mutations. The study consists of a main study phase and a long-term follow-up phase.",[28],[586,587],"gene therapy","GBA1-mutant Parkinson's disease","2026-06-29",{"date":590,"type":37},"2026-07-06",{"date":472,"type":22},{"date":593,"type":22},"2032-12-30",{"name":595,"class":154},"Lingyi Biotech Co., Ltd.",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":106,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":572},"100637666","phase-1-a-study-to-evaluate-satety-tolerability-biodistribution-radiation-dosimetry-and-pharmacokinetics-of-sst001-in-healthy-volunteers-patients-with-pd-and-patients-with-msa-100637666","NCT07604116","A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA","A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Sign the informed consent form approved by IEC.\n* Male or female participants aged ≥40 years old.\n* Adequate organ functions.\n* Proper contraception methods.\n* Willingness to follow the study procedures.\n* Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.\n* Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.\n* Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.\n\nExclusion Criteria:\n\n* Being pregnant or lactating.\n* History of other severe neurological disorders.\n* History of serious or uncontrolled medical condition.\n* Active HBV\u002FHCV\u002FHIV infection, etc.\n* History of abuse of drugs or alcohol within 1 year.\n* Allergy to the study drug.\n* Intolerance to PET\u002FCT or MRI (e.g. claustrophobia).\n* Any interventional clinical studies within 30 days.\n* Radiation exposure dose exceeding 50 mSv\u002Fyear.\n* Prior therapy targeting α-Syn.\n* Other ineligible conditions for this study.",{"count":604,"type":22},30,[110],"The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.",[608,28],"Multiple System Atrophy (MSA)",{"date":565,"type":37},{"date":611,"type":37},"2026-06-15",{"date":313,"type":22},{"name":614,"class":154},"Synusight Biotech (Shanghai) Co., Ltd.",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":627,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":634,"leadSponsor":635,"locationsCount":45},"100641386","comparison-of-two-different-dual-task-training-methods-in-patients-with-parkinsons-disease-100641386","NCT07641569","Comparison of Two Different Dual-Task Training Methods in Patients With Parkinson's Disease","Comparison of Motor-Motor and Cognitive-Motor Dual-Task Training in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Having been diagnosed with Parkinson's disease by a neurologist according to the UK Brain Bank criteria.\n* Being in stages 1-3 according to the Hoehn-Yahr Scale.\n\nExclusion Criteria:\n\n* Presence of a neurological disease other than Parkinson's disease\n* Cognitive impairment (Standardized Mini Mental Test score less than 24)\n* Having undergone deep brain stimulation surgery\n* Having a visual, auditory, or perceptual problem\n* Having any orthopedic, rheumatological, or other condition that may affect walking and balance.",{"count":623,"type":22},39,[25],"The aim of this study is to compare the effectiveness of motor-motor dual-task training and cognitive-motor dual-task training in patients with Parkinson's disease.The main questions it aims to answer are:\n\n\\- Whether there is a difference between motor-motor dual-task training and cognitive-motor dual-task training in patients with Parkinson's disease in terms of their effects on motor symptoms, balance, gait, functional mobility, activities of daily living, dual-task activities, cognitive functions, and balance confidence.\n\nResearchers will compare single-task training, motor-motor dual task training and cogvitive-motor dual task training.\n\nParticipants will:\n\n* Receive exercise training at the study clinic twice a week for approximately 45 minutes each time, for 6 weeks.\n* Participate in assessments at the study clinic before and after exercise training.",[28],[225,537,628,629],"Motor-Motor","Cognitive-Motor","2026-06-16",{"date":632,"type":37},"2026-06-18",{"date":611,"type":37},{"date":544,"type":22},{"name":546,"class":44},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":23,"phases":646,"briefSummary":647,"conditions":648,"keywords":650,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":45},"100609382","nutritional-intervention-for-constipation-symptoms-in-patients-with-parkinsons-disease-100609382","NCT07213856","Nutritional Intervention for Constipation Symptoms in Patients With Parkinson's Disease","Nutritional Intervention for Constipation Symptoms in Patients With Parkinson's Disease: A Randomized Clinical Trial","NUTRI-GUT-PD","Inclusion Criteria:\n\n* Adults with a previous diagnosis of Parkinson's disease\n* On a stable dose of levodopa for at least 3 months\n* Diagnosis of Functional Constipation by the Rome IV protocol\n\nExclusion Criteria:\n\n* Diagnosis of atypical or secondary parkinsonism\n* Hoehn and Yahr stage greater than 2\n* Presence of severe neurological or psychiatric disorders that impair the ability to participate in study procedures\n* Previous diagnosis of dementia\n* Presence of comorbidities such as active cancer, chronic obstructive pulmonary disease (COPD), heart failure, and\u002For chronic kidney disease\n* History of gastrointestinal cancers, inflammatory bowel diseases, or surgeries involving the gastrointestinal tract\n* Constipation secondary to clinical conditions such as hypothyroidism or diabetes mellitus\n* Use of opioids\n* Use of probiotics or antibiotics in the past 8 weeks\n* Continuous use of laxatives in the past 8 weeks\n* Presence of severe dysphagia according to the Functional Oral Intake Scale (FOIS)\n* Individuals receiving enteral or parenteral nutrition\n* Individuals under nutritional follow-up in the past 3 months",{"count":645,"type":22},54,[25],"The goal of this clinical trial is to evaluate whether a dietitian-guided nutritional intervention can improve constipation symptoms in people with Parkinson's disease (PD). The main questions it aims to answer are:\n\n* Can a dietitian-guided nutritional intervention increase the number of weekly bowel movements in individuals with PD and functional constipation?\n* Can this intervention positively influence gut microbiota composition, dietary intake, and nutritional status?\n\nResearchers will compare the intervention group to a control group that will receive general dietary guidance only after the study period, to see if the intervention leads to improvements in bowel function and related health outcomes.\n\nParticipants will:\n\n* Follow a diet plan developed by a dietitian, based on dietary reference intakes and tailored to the needs of individuals with PD and constipation\n* Participate in follow-up sessions with the dietitian for 3 months\n* Complete assessments at baseline, midpoint, and end of the intervention to evaluate bowel function, constipation symptoms, gut microbiota, nutritional status, and diet quality",[85,649],"Constipation - Functional",[651,652,653,654,655,656,657,658,659],"Microbiota","Diet","Diet, Protein-Restricted","Diet Therapy","Diet, Healthy","Nutrition Therapy","Constipation","Non-Motor Symptoms","Nutritionists",{"date":630,"type":37},{"date":662,"type":37},"2026-04-02",{"date":664,"type":22},"2029-08",{"name":666,"class":44},"Hospital de Clinicas de Porto Alegre"]